PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression

Xiao, Xiao; Lao, Xiang-Ming; Chen, Minmin; Liu, Ruixian; Yuan, Wei; Ouyang, Fang-Zhu; Chen, Dongping; Zhao, Xiao-Yu; Zhao, Qiyi; Li, Xuefeng; Liu, Chuan-Lu; Zheng, Limin; Kuang, Dong-Ming

doi:10.1158/2159-8290.cd-15-1408

Cited by 278 publications

(272 citation statements)

References 46 publications

Supporting

Mentioning

261

Contrasting

Unclassified

Order By: Relevance

“…Studies in human peripheral blood and tumour tissue have identified CD24 high CD38 high and PD-1 high regulatory B cells, respectively, and it has been suggested that, upon encountering external stimulus, these cells regulate T-cell responses by releasing protumorigenic IL-10192035. In our investigation, the FcγRII low/− activated B cells, without additional stimulation, could secrete IL-10 to repress tumour-specific cytotoxic T-cell response.…”

Section: Discussionmentioning

confidence: 56%

Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma

Ouyang

Yuan

et al. 2016

Nat Commun

Self Cite

View full text Add to dashboard Cite

B cells are prominent components of human solid tumours, but activation status and functions of these cells in human cancers remain elusive. Here we establish that over 50% B cells in hepatocellular carcinoma (HCC) exhibit an FcγRIIlow/− activated phenotype, and high infiltration of these cells positively correlates with cancer progression. Environmental semimature dendritic cells, but not macrophages, can operate in a CD95L-dependent pathway to generate FcγRIIlow/− activated B cells. Early activation of monocytes in cancer environments is critical for the generation of semimature dendritic cells and subsequent FcγRIIlow/− activated B cells. More importantly, the activated FcγRIIlow/− B cells from HCC tumours, but not the resting FcγRIIhigh B cells, without external stimulation suppress autologous tumour-specific cytotoxic T-cell immunity via IL-10 signals. Collectively, generation of FcγRIIlow/− activated B cells may represent a mechanism by which the immune activation is linked to immune tolerance in the tumour milieu.

show abstract

Section: Discussionmentioning

confidence: 56%

Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma

Ouyang

Yuan

et al. 2016

Nat Commun

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this issue of Cancer Discovery , Xiao and colleagues present a comprehensive study on a novel PD-1 high regulatory B cell subset in human hepatocellular carcinoma (7). This newly identified subset of PD-1 high regulatory B cell is correlated with the tumor stage and early recurrence of patients.…”

mentioning

confidence: 99%

PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment

Ren

Peng

2016

Cancer Discovery

View full text Add to dashboard Cite

show abstract

“…Expressed on normal tissues such as pancreas, colon, kidney tubules, bronchus, thyroid, and parathyroid glands [111]. …”

Section: Figurementioning

confidence: 99%

“…However, immunosuppressive tumor microenvironment undermines lymphocyte function. Myeloid derived suppressor cells [41], mesenchymal stem cells [117], regulatory T cells [108], cancer-associated fibroblasts [3], tumor associated macrophages [30], and programmed cell death protein 1 (PD-1) hi regulatory B cell [111] suppress immune cells and promote HCC progression. Furthermore, overexpression of inhibitory receptors including PD-1 and T cell immunoglobulin and mucin-domain containing-3 (TIM-3) on circulating or tumor-infiltrating T cells was associated with poor clinical outcomes [64, 100].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies

Hoseini

Cheung

2017

Cancer Letters

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide with an overall survival rate of less than 15% in developed countries. Despite attempts at new therapeutic strategies, the majority of patients succumb to this cancer. Buttressed by the highly successful clinical impact in melanoma, immunotherapy is gaining momentum as the next treatment modality for many human cancers. Chimeric antigen receptors (CAR) contain the antigen binding moieties of a monoclonal antibody and the co-stimulatory and signaling domains associated with effector receptor signaling. Bispecific antibodies (BsAb) combine the binding specificities of two different monoclonal antibodies, one activating a receptor on a killer effector cell, while the other engaging a tumor-associated antigen to initiate tumor cytotoxicity. In this review, we survey the HCC targets for which CARs and bispecific antibodies have been generated. The pros and cons of these targets for T-cell and Natural Killer cell based immunotherapy will be discussed.

show abstract

PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression

Cited by 278 publications

References 46 publications

Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma

Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma

PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment

Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies

Contact Info

Product

Resources

About